Publication dates

All regions

Ovarian Cancer Industry, October 2014 Market Reports from Top Publishers

You might be interested in: cancer, medical equipment, therapeutics, more »


 
1-20 of about 5 900 reports for Ovarian Cancer

Aposense Ltd. (Symbol:APOS) SWOT Analysis, Strategy, Revenues and Profits

Aposense Ltd. (Symbol:APOS) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • October 2014
  • by Global Data

... Of parkinson's disease. The company's att-11t is a therapeutic compound used in the treatment of metastatic solid tumors such as colorectal cancer, lung cancer and ovarian cancer. It markets products through ...

HealthLinx Limited (Symbol:HTX) SWOT Analysis, Strategy, Revenues and Profits

HealthLinx Limited (Symbol:HTX) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • October 2014
  • by Global Data

... And diagnostic products. Its products include cr0014, ovplex, and clear it. Healthlinx's cr014 is an inhibitor of vascular leak; ovplex is a multimarker blood test for ovarian cancer; and clear it is a protein ...

OXiGENE, Inc. (Symbol:OXGN) SWOT Analysis, Strategy, Revenues and Profits

OXiGENE, Inc. (Symbol:OXGN) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • October 2014
  • by Global Data

... Trials for the treatment of ovarian cancer, anaplastic thyroid cancer, medullary thyroid cancer, stage iv papillary thyroid cancer, and stage iv follicular thyroid cancer. The company also offers falcon ...

Viralytics Ltd. (Symbol:VLA) SWOT Analysis, Strategy, Revenues and Profits

Viralytics Ltd. (Symbol:VLA) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • October 2014
  • by Global Data

... Also provides virotherapy technology that uses group of viruses to target cancer cells. It conducts cancer research on gastric cancer with evatak, ovarian cancer with evatak, and melanoma studies ...

TapImmune Inc. (Symbol:TPIV) SWOT Analysis, Strategy, Revenues and Profits

TapImmune Inc. (Symbol:TPIV) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • October 2014
  • by Global Data

... In legal dispute with michael gardnerjul 23, 2014: new immunotherapy technologies provide hope in breast and ovarian cancerjun 12, 2014: tapimmune appoints leading immunotherapy researcher to chair ...

Tikcro Technologies, Ltd. (Symbol:TIKRF) SWOT Analysis, Strategy, Revenues and Profits

Tikcro Technologies, Ltd. (Symbol:TIKRF) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • October 2014
  • by Global Data

... Phase ii/b clinical trials for the treatment of pancreatic cancer and for superficial bladder carcinoma cancer, as well as a phase i/iia clinical trial for the treatment of ovarian cancer. Tikcro ...

Galena Biopharma, Inc. (GALE) - Financial and Strategic SWOT Analysis Review

Galena Biopharma, Inc. (GALE) - Financial and Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • October 2014
  • by Global Data

... Vax hercepti for the treatment of breast cancer and folate binding protein for the treatment of endometrial and ovarian cancer. Galena's abstral is a sublingual tablets for the management of breakthrough pain ...

Prima BioMed Ltd. (PRR) - Financial and Strategic SWOT Analysis Review

Prima BioMed Ltd. (PRR) - Financial and Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • October 2014
  • by Global Data

... Immunocellular therapeutic products for cancer treatment. Its cvac therapy is an immunocellular therapeutic under investigation for the treatment of epithelial ovarian cancer. Prima biomed also provides dendritic ...

MEI Pharma, Inc. (MEIP) - Financial and Strategic SWOT Analysis Review

MEI Pharma, Inc. (MEIP) - Financial and Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • October 2014
  • by Global Data

... Of cancer. The company's pwt143 is a pre-clinical development for the treatment of cancer. Its compounds are used for the treatment of prostate and ovarian cancer. The company operates as a subsidiary ...

VG Life Sciences, Inc. (VGLS) - Financial and Strategic SWOT Analysis Review

VG Life Sciences, Inc. (VGLS) - Financial and Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • October 2014
  • by Global Data

... In the therapeutic areas of ovarian cancer and breast cancer, lyme disease, hiv/aids, sepsis, staph/strep infection, pandas, among others. The company conducts research and development program based on technology ...

About 800 reports for Ovarian Cancer

Download Unlimited Documents from Trusted Public Sources

Pathology Description in the US

  • Medical Policy
  • August 2014
    25 pages
  • Cancer  

    Breast Cancer  

  • United States  

View report >

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.